DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Lung Cancer
Advanced Non Small Cell Lung Cancer
Unresectable Non-small Lung Cancer

Interventions: Drug: DS-1062a

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 100

Registration Number: NCT04940325

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷
Gustave Roussy, Villejuif, France

and more 6 locations

Gustave Roussy Cancer Profiling

Phase 1

Recruiting

Conditions: Solid Tumor, Unspecified, Adult

Interventions: Procedure: Biopsy

First Posted Date: 2021-06-21

Last Posted Date: 2024-08-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 10000

Registration Number: NCT04932525

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: indocyanine green

First Posted Date: 2021-04-13

Last Posted Date: 2025-04-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 65

Registration Number: NCT04842162

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇧🇪
Institut Jules Bordet, Anderlecht, Belgium

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Phase 2

Terminated

Conditions: Peritoneal Carcinomatosis

Interventions: Other: Saline water
Drug: Pasireotide 0.9 MG/ML

First Posted Date: 2021-04-01

Last Posted Date: 2024-02-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 6

Registration Number: NCT04826432

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: AsiDNA
Drug: Niraparib
Drug: Olaparib
Drug: Rucaparib

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 13

Registration Number: NCT04826198

Locations: 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷
Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷
Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France

and more 3 locations

USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY

Conditions: Mandibular Osteoradionecrosis

Interventions: Other: Data collection

First Posted Date: 2021-04-01

Last Posted Date: 2021-04-01

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 75

Registration Number: NCT04826445

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2021-03-30

Last Posted Date: 2024-07-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 27

Registration Number: NCT04823403

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Phase 2

Suspended

Conditions: Biliary Tract Cancer
Gastro-oesophageal Adenocarcinoma
Head and Neck Cancer
Urothelial Bladder Cancer
Clear Cell Renal Cell Carcinoma
Gastric Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Platinum-sensitive Urothelial Bladder Cancer

Interventions: Drug: Dostarlimab
Drug: Niraparib

First Posted Date: 2021-03-03

Last Posted Date: 2024-03-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 51

Registration Number: NCT04779151

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia

Not Applicable

Completed

Conditions: Myelomonocytic Leukemia

Interventions: Other: Deuterium Glucose

First Posted Date: 2021-03-01

Last Posted Date: 2024-05-24

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 39

Registration Number: NCT04775121

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Hôpital Saint Louis, Paris, France

Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

Recruiting

Conditions: Cancer

Interventions: Other: Stool
Other: Blood sample

First Posted Date: 2020-09-28

Last Posted Date: 2024-06-12

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1100

Registration Number: NCT04567446

Locations: 🇫🇷
Hôpital Foch, Suresnes, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Clinique du Flandre, Coudekerque-Branche, France

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy